Navigation Links
Shire plc: Continued Strong Product Sales Performance in Q3: On Track to Deliver Significant 2011 Earnings Growth
Date:10/28/2011

and establishment of an international commercial hub in Switzerland, gain on disposal of investment in Vertex ($23.5 million), and tax effect of adjustments; and

d)Depreciation: Depreciation of $30.9 million included in Cost of product sales, R&D costs and SG&A costs for US GAAP separately disclosed for the presentation of Non GAAP earnings.


 

Unaudited results for the three months to September 30, 2010

Non GAAP reconciliation

US GAAP Adjustments Non GAAP Acquis Divestments, Amorti itions & reorgan September -zation integr -izations & Reclas September 3 months to, 30, & asset -ation discontinued -sify 30, 2010 impairments activ operations deprec 2010 -ities -iation (a) (b) (c) (d) $M $M $M $M $M $M Total revenues 874.3 - - - - 874.3 Costs and expenses: Cost of product sales 112.7 - - (7.3) (2.3) 103.1 Research and development 197.9 - (45.0) - (4.4) 148.5 Selling, general and administrative 392.4 (73.9) - - (16.1) 302.4 Reorganization costs 9.7 - - (9.7) - - Integration and acquisition costs 5.8 - (5.8) - - - Depreciation - - - - 22.8 22.8 Total operating expenses 718.5 (73.9) (50.8) (17.0) - 576.8 Operating income 155.8 73.9 50.8 17.0 - 297.5 Interest income 1.0 - - - - 1.0 Interest expense (8.3) - - - - (8.3) Other income, net 0.8 - - - - 0.8 Total other expense, net (6.5) - - - - (6.5) Income before income taxes and equity in losses of equity method investees 149.3 73.9 50.8 17.0 - 291.0 Income taxes (52.7) (10.1) (3.5) (4.1) - (70.4) Equity in losses of equity method investees, net of tax (0.3) - - - - (0.3) Net income 96.3 63.8 47.3 12.9 - 220.3 Impact of convertible debt, net of tax (1) - 8.4 - - - 8.4 Numerator for diluted EPS 96.3 72.2 47.3 12.9 - 228.7 Weighted average number of shares (millions) - diluted 556.7 33.2 - - - 589.9 Diluted earnings per ADS 51.9c 33.8c 24.0c 6.6c - 116.3c

(1)    The impact of convertible debt, net of tax has a dilutive effec
'/>"/>

SOURCE Shire plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31

Related biology technology :

1. NHS Northamptonshire Chief Executive John Parkes Accepts Visiting Professorship
2. FDA Approves Shires FIRAZYR® (icatibant injection) for Acute Attacks of Hereditary Angioedema (HAE)
3. Shires Quarterly Revenues Grow by 25% to $1 Billion for the First Time
4. Shire Files Lawsuits Against Watson and Roxane for Infringement of VYVANSE(R) (lisdexamfetamine dimesylate) Patents
5. Shire Presents Data at ACMG for Fabry and Gaucher Patients Who Switched to Replagal® (agalsidase alfa) and VPRIV® (velaglucerase alfa for injection)
6. Shire Reports Positive Signal Finding Study of Investigative Use of Vyvanse(R) (lisdexamfetamine dimesylate) Capsules as Adjunctive Treatment in Major Depressive Disorder
7. Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging
8. Shire Announces Results of the Tender Offer for Movetis NV and Commencement of Squeeze-Out Tender Period
9. Reportlinker Adds Shire plc: PharmaVitae Profile
10. Shire Announces European Approval of VPRIV(R) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease
11. Shire plc - Statement re ProAmatine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2015)... , Aug. 26, 2015  Platform therapeutic ... it has received a $1.5M Phase II SBIR ... to further develop its therapeutic agent to reduce ... need in end stage renal disease (ESRD) patients ... National Institute of Diabetes and Digestive and Kidney ...
(Date:8/26/2015)... After litigating and negotiating patent infringement ... P2i United States patent RE43,651 (the ... the United States without any admission or ... party. As a result of the parties, settlement, the US ... dismissed the case without prejudice. Under ...
(Date:8/25/2015)... , Aug. 25, 2015   WuXi PharmaTech (Cayman) ... capability and technology platform company serving the pharmaceutical, biotechnology, ... ("Lee,s Pharm," Hong Kong Exchange Stock Code: 0950), a ... with 20 years of operations in ... companies have signed an agreement whereby WuXi,s Laboratory Testing ...
(Date:8/25/2015)... ... 2015 , ... One of the world’s foremost authorities on supply chain risk ... been on a mission for the past two weeks. She’s been scrambling to warn ... the two massive explosions that occurred on August 12 at the Ruihai International Logistics ...
Breaking Biology Technology:Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 2Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 3P2i Settles United States Litigation 2WuXi PharmaTech to Be Exclusive Supplier of Laboratory Testing Services to Lee's Pharm 2WuXi PharmaTech to Be Exclusive Supplier of Laboratory Testing Services to Lee's Pharm 3Resilinc Supply Chain Expert Warns: Impact of Tianjin Chemical Explosions Will be Far Worse than Reported 2Resilinc Supply Chain Expert Warns: Impact of Tianjin Chemical Explosions Will be Far Worse than Reported 3Resilinc Supply Chain Expert Warns: Impact of Tianjin Chemical Explosions Will be Far Worse than Reported 4
... and PARSIPPANY, N.J., May 12 Forest,Laboratories, ... pharmaceutical company, and,Daiichi Sankyo, Inc. today announced ... AZOR(TM)* (amlodipine and olmesartan medoxomil),Daiichi Sankyo,s fixed-dose ... amlodipine besylate and the angiotensin receptor,blocker olmesartan ...
... elution technology to ... reduce and sustain intraocular pressure, VANCOUVER, May 12 ... results from a proof of concept trial conducted by,QLT,s ... plug,drug delivery technology. The results demonstrated that QLT,s drug ...
... WaferGen Biosystems,Inc. (OTC Bulletin Board: WGBS), a leading ... stem cell research systems,today announced that Mr. Alnoor ... corporate presentation at the Rodman & Renshaw,Fifth Annual ... May,19-20, 2008, at the Le Meridien Beach Plaza ...
Cached Biology Technology:Forest Laboratories, Inc. and Daiichi Sankyo, Inc. Announce the Termination of the AZOR Co-Promotion Agreement 2Forest Laboratories, Inc. and Daiichi Sankyo, Inc. Announce the Termination of the AZOR Co-Promotion Agreement 3Forest Laboratories, Inc. and Daiichi Sankyo, Inc. Announce the Termination of the AZOR Co-Promotion Agreement 4QLT reports initial proof of concept data for punctal plug delivery technology 2QLT reports initial proof of concept data for punctal plug delivery technology 3QLT reports initial proof of concept data for punctal plug delivery technology 4WaferGen to Present at the Rodman and Renshaw Fifth Annual Global Healthcare Conference 2
(Date:8/10/2015)... Germany , August 10, 2015 ... in Eye Tracking Technology for more than two decades, ... Platform for integration into all consumer display formats. The ... seamless integration of eye tracking into consumer tablets, laptops, ... reality smart glasses. Omnivision,s leading sensor technology contributes to ...
(Date:8/6/2015)... 2015 Synaptics Inc. (NASDAQ: SYNA ... today announced collaboration with Microsoft on biometric fingerprint ... leveraged Synaptics, deep expertise in human interface which ... Through stringent testing, Synaptics, advanced image sensing ... Precision TouchPad (PTP) specification empowering OEMs with Windows ...
(Date:8/4/2015)... , Aug. 04, 2015 ... http://www.researchandmarkets.com/research/nvh7k2/digital_forensics ) has announced the addition of ... (Hardware, Software, and Service), Sub-Segment (Computer Forensics, ... Forensics), Tool Types, Service, Vertical and Region ... to their offering. By Component ...
Breaking Biology News(10 mins):SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3Synaptics Chosen for Human Interface Co-Development on Windows 10 2Digital Forensics Market - The Market Represents a Compound Annual Growth Rate (CAGR) of 11.3% From 2015 to 2020 2
... big effect on their life. Some people are outgoing ... can be detrimental to their health and wellbeing. Increasingly, ... , A new study led by Dr Kathryn Arnold, ... has added important experimental evidence showing that animal personalities ...
... NY, April 27, 2011An international team of scientists, led by ... has used DNA to determine that groups of dusky ... brachyurus ) living in different coastal regions across the globe ... predators that are heavily exploited for the shark fin trade, ...
... PHILADELPHIA A Philadelphia botanist who has studied rare plants for ... plant named for him is finally getting his due, but with ... again. Dr. Alfred "Ernie" Schuyler, emeritus curator of botany ... rare plants, recently was honored when a colleague discovered a new ...
Cached Biology News:Animals have personalities, too 2Scientists can track origin of shark fins using 'zip codes' in their DNA 2Scientists can track origin of shark fins using 'zip codes' in their DNA 3Rare Pennsylvania fungus is named for Philadelphia botanist 2
MpV17 transgene, murine homolog, glomerulosclerosis...
... Ambion's custom siRNA service provides the ... gene silencing research. Custom siRNAs can be ... 19-21 base target sequence, or by providing ... check out Ambion's Silencer Validated and Silencer ...
Human SDNSF/MCFD2 Biotinylated Affinity Purified PAb...
8.1.1...
Biology Products: